318 related articles for article (PubMed ID: 20682973)
1. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Cho YH; Yazici H; Wu HC; Terry MB; Gonzalez K; Qu M; Dalay N; Santella RM
Anticancer Res; 2010 Jul; 30(7):2489-96. PubMed ID: 20682973
[TBL] [Abstract][Full Text] [Related]
2. [Detection of free tumor-related DNA in the serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Deng GR
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
4. Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls.
Sturgeon SR; Balasubramanian R; Schairer C; Muss HB; Ziegler RG; Arcaro KF
Epigenetics; 2012 Nov; 7(11):1258-67. PubMed ID: 22986510
[TBL] [Abstract][Full Text] [Related]
5. [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Xu GW; Deng GR
Ai Zheng; 2007 Jan; 26(1):44-7. PubMed ID: 17222366
[TBL] [Abstract][Full Text] [Related]
6. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients.
Shukla S; Mirza S; Sharma G; Parshad R; Gupta SD; Ralhan R
Epigenetics; 2006; 1(2):88-93. PubMed ID: 17998817
[TBL] [Abstract][Full Text] [Related]
7. Promoter Hypermethylation in White Blood Cell DNA and Breast Cancer Risk.
Cho YH; McCullough LE; Gammon MD; Wu HC; Zhang YJ; Wang Q; Xu X; Teitelbaum SL; Neugut AI; Chen J; Santella RM
J Cancer; 2015; 6(9):819-24. PubMed ID: 26284132
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Spitzwieser M; Entfellner E; Werner B; Pulverer W; Pfeiler G; Hacker S; Cichna-Markl M
BMC Cancer; 2017 Apr; 17(1):260. PubMed ID: 28403857
[TBL] [Abstract][Full Text] [Related]
9. Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.
Brennan K; Garcia-Closas M; Orr N; Fletcher O; Jones M; Ashworth A; Swerdlow A; Thorne H; ; Riboli E; Vineis P; Dorronsoro M; Clavel-Chapelon F; Panico S; Onland-Moret NC; Trichopoulos D; Kaaks R; Khaw KT; Brown R; Flanagan JM
Cancer Res; 2012 May; 72(9):2304-13. PubMed ID: 22374981
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients.
Mirza S; Sharma G; Parshad R; Srivastava A; Gupta SD; Ralhan R
Ann Surg Oncol; 2012 Sep; 19(9):3107-15. PubMed ID: 22451234
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry.
Yazici H; Terry MB; Cho YH; Senie RT; Liao Y; Andrulis I; Santella RM
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2723-5. PubMed ID: 19755643
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
13. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
14. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
15. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma.
Jing F; Yuping W; Yong C; Jie L; Jun L; Xuanbing T; Lihua H
Tumour Biol; 2010 Aug; 31(4):321-31. PubMed ID: 20490964
[TBL] [Abstract][Full Text] [Related]
16. LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients.
Akers SN; Moysich K; Zhang W; Collamat Lai G; Miller A; Lele S; Odunsi K; Karpf AR
Gynecol Oncol; 2014 Feb; 132(2):462-7. PubMed ID: 24374023
[TBL] [Abstract][Full Text] [Related]
17. Promoter CpG island hypermethylation during breast cancer progression.
Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
[TBL] [Abstract][Full Text] [Related]
18. High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer.
Yeo W; Wong WL; Wong N; Law BK; Tse GM; Zhong S
Pathology; 2005 Apr; 37(2):125-30. PubMed ID: 16028839
[TBL] [Abstract][Full Text] [Related]
19. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
